Pluri Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$2.45next fiscal year
Monitoring Framework
Key Performance Indicators
Cellav Product Commercialization (Regenativo+ and Placento+) QuarterlyTarget: Secure initial commercial orders and expand adoption among licensed aesthetic professionals in the U.S. market
EIB Loan Restructuring Status Monthly20MTarget: Reach a mutually acceptable repayment or extension agreement with the European Investment Bank
Trailing Twelve Months (TTM) Revenue Quarterly1.1MTarget: Achieve significant top-line growth driven by CDMO services and commercial launches
Watch Items
- European Investment Bank (EIB) €20 million loan repayment negotiationsTrigger: Failure to reach an agreement by the July 3, 2026 deadlineAction: Assess liquidity risk, potential enforcement actions, and alternative debt or equity financing options
- Nasdaq Minimum Market Value of Listed Securities (MVLS) ComplianceTrigger: Market value of listed securities falling below $35 million or failure to meet alternative listing standardsAction: Monitor share price and execute strategic plans to maintain compliance with Nasdaq Capital Market requirements
Research as of 20 Jun 2026